←Back to Expert Scholars
Translational Medicine / 转化医学Lung Cancer Clinical Trials
Tony Mok
MD
🏢Chinese University of Hong Kong🌐Hong Kong
Li Shu Fan Medical Foundation Professor of Clinical Oncology
130
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Tony Mok led pivotal lung cancer trials including KEYNOTE-042 demonstrating pembrolizumab benefit across broader PD-L1 positive NSCLC populations and the IPASS EGFR trial that transformed targeted therapy. He has shaped Asian and global lung cancer practice.
Share:
🧪Research Fields 研究领域
NSCLC trials
KEYNOTE-042
EGFR mutation
Asian lung cancer
immunotherapy Asia
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Tony Mok 的研究动态
Follow Tony Mok's research updates
留下邮箱，当我们发布与 Tony Mok（Chinese University of Hong Kong）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment